70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer-Reference-Cited by-同舟云学术

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Published:2016-08-25 Issue:8 Volume:375 Page:717-729
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Cardoso Fatima,van’t Veer Laura J.,Bogaerts Jan,Slaets Leen,Viale Giuseppe,Delaloge Suzette,Pierga Jean-Yves,Brain Etienne,Causeret Sylvain,DeLorenzi Mauro,Glas Annuska M.,Golfinopoulos Vassilis,Goulioti Theodora,Knox Susan,Matos Erika,Meulemans Bart,Neijenhuis Peter A.,Nitz Ulrike,Passalacqua Rodolfo,Ravdin Peter,Rubio Isabel T.,Saghatchian Mahasti,Smilde Tineke J.,Sotiriou Christos,Stork Lisette,Straehle Carolyn,Thomas Geraldine,Thompson Alastair M.,van der Hoeven Jacobus M.,Vuylsteke Peter,Bernards René,Tryfonidis Konstantinos,Rutgers Emiel,Piccart Martine

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1602253

Cited by 1435 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts;Translational Oncology;2024-10

2. The impact of extensive intraductal component (EIC) on the genomic risk of recurrence in early hormone receptor positive breast cancer;The Breast;2024-10

3. Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

4. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

5. Improving data interpretability with new differential sample variance gene set tests;2024-09-09